Products of thymine oxygenation by a non-heme oxygenation model, Fe II(MeCN)62+-Ac2O-H2O 2, and the transition state model between oxoiron and thymine

Chemical and Pharmaceutical Bulletin

Volumn 58, Issue 6, 2010, Pages 775-781

  Kobayashi, Shigeki ^a   Takagi, Akihiko ^a   Chikuma, Toshiyuki ^a   Tamura, Osamu ^a   Kotani, Eiichi ^a   Katase, Takao ^b  

^a SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^b NIHON UNIVERSITY   (Japan)

Author keywords

DNA damage; Iron(II) hexakisacetonitrile; Oxoiron; Thymine glycol; Transition state

Indexed keywords

1,3 DIMETHYLTHYMINE; IRON; OXOIRON; SCAVENGER; THYMINE; THYMINE DERIVATIVE; THYMINE GLYCOL DERIVATIVE; TRANS 5,6 DIACETOXY 1 ACETYL 5,6 DEHYDROTHYMINE; UNCLASSIFIED DRUG; IRON DERIVATIVE; THYMINE GLYCOL;

ARTICLE; CHEMICAL MODEL; DNA DAMAGE; ELECTRON; OXYGENATION; PHASE TRANSITION; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; CHEMISTRY; OXIDATION REDUCTION REACTION;

DNA DAMAGE; IRON COMPOUNDS; MODELS, BIOLOGICAL; OXIDATION-REDUCTION; THYMINE;

EID: 77953149719     PISSN: 00092363     EISSN: 13475223     Source Type: Journal    
DOI: 10.1248/cpb.58.775     Document Type: Article

References (30)

1. Beckman K. B., Ames B. N., J. Biol. Chem., 272, 19633-19636 (1997).
2. Aust A. E., Eveleigh J. F., Proc. Soc. Exp. Biol. Med., 222, 246-252 (1999).
3. Valko M., Izakovic M., Mazur M., Rhodes C. J., Telser J., Mol. Cell. Biochem., 266, 37-56 (2004).
4. Cadet J., Guttin-Lombard M., Teoule R., Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med., 30, 1-11 (1976).
5. Frelon S., Douki T., Favier A., Cadet J., J. Chem. Soc., Perkin Trans. 1, 2002, 2866-2870 (2002).
6. Zhang Q., Wang Y., J. Am. Chem. Soc., 126, 13287-13297 (2004).
7. Aruoma O. I., Halliwell B., Chem. Br., 27, 149-152 (1991).
8. Koppenol W. H., Redox Rep., 6, 229-234 (2001).
9. Harayama T., Kotoji K., Yanada R., Yoneda F., Taga T., Osaki K., Tomohisa H., Chem. Pharm. Bull., 34, 2354-2361 (1986).
10. Henle E. S., Han Z., Tang N., Rai P., Luo Y., Linn S., J. Biol. Chem., 274, 962-971 (1999).
11. Umemura T., Sai K., Takagi A., Hasegawa R., Kurokawa Y., Carcinogenesis, 11, 345-347 (1990).
12. Kasai H., Nishimura S., Nucleic Acids Res., 12, 2137-2147 (1984).
13. Miller H., Fernandes A. S., Zaika E., McTigue M. M., Torres M. C., Wente M., Iden C. R., Grollman A. P., Nucleic Acids Res., 32, 338-345 (2004).
14. Stephenson N. A., Bell A. T., Inorg. Chem., 45, 2278-2285 (2007).
15. Groves J. T., J. Inorg. Biochem., 100, 434-447 (2006).
16. Cathcart R., Schwiers E., Soul R. L.,Ames B. N., Proc. Natl. Acad. Sci. U.S.A., 81, 5633-5637 (1984).
17. Miller H., Fernandes A. S., Zaika E., McTigue M. M., Torres M. C., Wente M., Iden C. R., Grollman A. P., Nucleic Acids Res., 32, 338-345 (2004).
18. Takao K., Kanno S., Shiromoto T., Hasegawa R., Ide H., Ikeda S., Sarker A. H., Seki S., Xing J. Z., Le X. C., Weinfeld M., Kobayashi K., Miyazaki J., Muijtjens M., Hoeijmakers J. H., van der Horst H. G., Yasui A., Sarker A. H., EMBO J., 21, 3486-3493 (2002).
19. Kotani E., Kobayashi S., Ishii Y., Tobinaga S., Chem. Pharm. Bull., 32, 4281-4291 (1984).
20. Kotani E., Kobayashi S., Ishii Y., Tobinaga S., Chem. Pharm. Bull., 33, 4671-4679 (1985).
21. Kobayashi S., Kotani E., Ishii Y., Tobinaga S., Chem. Pharm. Bull., 37, 610-614 (1989).
22. Kotani E., Yakugaku Zasshi, 124, 873-892 (2004).
23. Benn M. H., Chatamra B., Jones A. S., J. Chem. Soc., 1960, 1014-1020 (1960).
24. Iida S., Hayatsu H., Biochem. Biophys. Acta, 213, 1-13 (1970).
25. Itahara T., Fujii Y., Tada M., J. Org. Chem., 53, 3421-3424 (1988).
26. Stoyanov S. R., Villegas J. M., Rillema D. P., Inorg. Chem., 41, 2941-2945 (2002).
27. Howell J. O., Goncalves J. M., Amatore C., Klasinc L., Wightman R. M., Kochi J. K., J. Am. Chem. Soc., 106, 3968-3976 (1984).
28. Hay P. J., Wadt W. R., J. Chem. Phys., 82, 299-310 (1985).
29. Rohde J.-U., Torelli S., Shan X., Lim M. H., Klinker E. J., Kaizer J., Chen K., Nam W., Que L. Jr., J. Am. Chem. Soc., 126, 16750-16761 (2004).
30. Titan and Spartan06, Wavefunction, Inc., Irvine, CA, U.S.A.